Patients with Crohn's Disease Are More Likely to Remain on Biologics than Immunomodulators: A Meta-Analysis of Treatment Durability

Digestive Diseases and Sciences
Eric D ShahGil Y Melmed

Abstract

The comparative effectiveness of treatments for moderate-to-severe Crohn's disease can be influenced by the likelihood of remaining on medication. We aimed to clarify this treatment durability by assessing subject discontinuations from clinical trials in the context of treatment efficacy. We conducted a literature search for double-blind RCT of Crohn's disease therapies recommended in international guidelines or with recent positive phase III trial results. Durability was defined through study discontinuation due to adverse events or disease exacerbation represented by number needed to discontinue (NND). Efficacy was defined as clinical remission represented by number needed to treat (NNT). The primary endpoint was NND/NNT, with a higher value representing more durable and effective treatment. Treatment with azathioprine/6-mercaptopurine (AZA/6MP) was associated with more discontinuations than with clinical remission (NND/NNT = 0.92) in maintenance trials. For induction, methotrexate was associated with similar rates of discontinuations and remission (NND/NNT = 1.4). In one maintenance trial, the remission rate for methotrexate was greater than the study discontinuation rate (NND/NNT = 23.3). In contrast, anti-TNF trials reveal...Continue Reading

References

Aug 1, 1975·The American Journal of Digestive Diseases·J L RosenbergJ B Kirsner
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Oct 30, 1971·Lancet·J M WilloughbyA M Dawson
Feb 2, 1995·The New England Journal of Medicine·B G FeaganM Hopkins
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Jan 3, 2003·The New England Journal of Medicine·Subrata GhoshUNKNOWN Natalizumab Pan-European Study Group
Oct 16, 2003·Pharmacoepidemiology and Drug Safety·William L HoldenWanju Dai
Apr 30, 2004·Statistics in Medicine·Michael J SweetingPaul C Lambert
Nov 4, 2005·The New England Journal of Medicine·William J SandbornUNKNOWN Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group
Dec 14, 2005·Statistics in Medicine·Roger M HarbordJonathan A C Sterne
May 2, 2007·Annals of Internal Medicine·William J SandbornPaul F Pollack
May 9, 2007·Gastroenterology·Stephan R TarganUNKNOWN International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group
Jul 20, 2007·The New England Journal of Medicine·William J SandbornUNKNOWN PRECISE 1 Study Investigators
Jul 20, 2007·The New England Journal of Medicine·Stefan SchreiberUNKNOWN PRECISE 2 Study Investigators
Apr 19, 2008·BMC Musculoskeletal Disorders·Alberto Alonso-RuizAntonio Quintana
Oct 3, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Brian G FeaganAsit Parikh
Jan 29, 2009·The American Journal of Gastroenterology·Gary R LichtensteinUNKNOWN Practice Parameters Committee of American College of Gastroenterology
Dec 10, 2009·The American Journal of Gastroenterology·C A JacksonRob Horne
Apr 16, 2010·The New England Journal of Medicine·Jean Frédéric ColombelUNKNOWN SONIC Study Group
Dec 3, 2010·Journal of Crohn's & Colitis·A DignassUNKNOWN European Crohn's and Colitis Organisation (ECCO)
Jun 7, 2011·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·William J SandbornGeert R D'Haens
Aug 6, 2011·Journal of Clinical Epidemiology·Daniel SuissaSamy Suissa
Sep 29, 2011·Gastroenterology·Edouard LouisUNKNOWN Groupe D'etudes Thérapeutiques Des Affections Inflammatoires Digestives
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Feb 14, 2012·Journal of Crohn's & Colitis·Mamoru WatanabeUNKNOWN Study Investigators
Mar 27, 2012·The American Journal of Medicine·Eric ShahMark Pimentel
Mar 13, 2013·Inflammatory Bowel Diseases·Millie D LongMichael D Kappelman
Jul 13, 2013·Journal of Crohn's & Colitis·M-A MeuwisUNKNOWN GETAID (Groupe d'Étude Thérapeutique Des Affections Inflammatoires Digestives)
Aug 24, 2013·The New England Journal of Medicine·William J SandbornUNKNOWN GEMINI 2 Study Group

❮ Previous
Next ❯

Citations

Nov 11, 2017·Clinical Pharmacology in Drug Development·Jonathan Q TranPaul A Frohna
Jul 14, 2019·Inflammatory Bowel Diseases·Kara Mari De Felice

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.